Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 15

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 15
---
 appraisal rights?

A:MIRA shareholders are not entitled to appraisal rights. See the section of this proxy statement titled “ Appraisal Rights and Dissenters’ Rights”on page 36.

Q: Have SKNY’s stockholders agreed to adopt the Merger Agreement?

A:Yes. On June 9, 2025, SKNY’s stockholders adopted the Merger Agreement and approved the Merger and the other Contemplated Transactions via the SKNY Stockholder Written Consent (as defined below). For more information on the matters approved by the stockholders of SKNY please see the sections titled “ The Merger Agreement—Conditions to the Merger.”

Q: Who can help answer my questions?

A:If you are a holder of MIRA Common Stock as of the record date and would like additional copies, without charge, of this proxy statement or if you have questions about the Merger, including the procedures for voting your shares, you should contact MIRA at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida, (786) 432-9792.

| 5 |

<div align='center'>SUMMARY</div>

This summary highlights selected information from this proxy statement and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the MIRA virtual special meeting, you should read this entire proxy statement carefully, including the Merger Agreement attached as Annex A, the valuation report of SKNY Pharmaceuticals, Inc. attached as Annex B, the valuation report for MIRA Pharmaceuticals Inc. is attached as Annex C, the fairness opinion for the Merger is attached as Annex D and the SKNY-1 License Agreement is attached as Annex E. For more information, please see the section titled “Where You Can Find More Information” beginning on page 56 of this proxy statement.

The Companies

MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida

(786) 432-9792

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function.

Ketamir-2: A Novel Oral Ketamine Analog